3-(4-(3-(ethylsulfonyl)propyl)bicyclo[2.2.2]octan-1-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-4H-1,2,4-triazole
MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).